Laplace Interventional

About Laplace Interventional

Based in Minneapolis, Laplace Interventional, Inc. is a medical device company established in August 2020 by Founder and CEO Ramji Iyer, PhD. Dr. Iyer, who holds a doctorate in mechanical engineering, leveraged over a decade of experience in heart valve development, including a key role at LivaNova (Caisson Interventional), to launch the venture. His background in both large corporations like St. Jude Medical and startup environments provided the foundation for addressing a critical unmet need in structural heart disease.

The company is focused on developing a treatment for Tricuspid Regurgitation (TR), a condition where the heart's tricuspid valve leaks, leading to potential right-side heart failure. The market for this condition is substantial, with a high mortality rate for untreated patients. Laplace Interventional's core product is a Transcatheter Tricuspid Valve Replacement (TTVR) system. This system is designed to deliver a prosthetic valve through a patient's vasculature, a minimally invasive procedure that avoids the need for open-heart surgery and aims to reduce associated complications. The primary clients are medical professionals and institutions, specifically interventional cardiologists and hospitals that treat cardiovascular conditions. The company's business model is centered on research and development, with future revenue contingent on the commercialization of its TTVR system following regulatory approvals.

Laplace has made significant progress in its funding and clinical development. The company secured a $7.9M Series A in September 2021, a $12.9M Series B in July 2023, and a $22M Series C in March 2025, attracting investments from firms like ShangBay Capital, Features Capital, Boston Scientific, and Mayo Clinic. A major milestone was achieved in February 2024 with the successful completion of the first-in-human procedure as part of an FDA-approved Early Feasibility Study (EFS). This study is designed to evaluate the safety and technical feasibility of the TTVR system. The company is now using its funding to complete the EFS and prepare for a pivotal clinical trial, which is a crucial step toward gaining market approval. It is important to note that the Laplace TTVR system is an investigational device and is not yet approved or cleared for sale by the FDA or other global regulatory bodies.